Neptune Technologies & Bioressources Inc. and Acasti Pharma Inc. to Present at the 2011 Scientific Sessions of the American Hear
March 24 2011 - 8:00AM
Neptune Technologies & Bioressources Inc. ("Neptune")
(Nasdaq:NEPT) (TSX-V:NTB) and its subsidiary Acasti Pharma Inc.
("Acasti") are pleased to announce the presentations of clinical
and recent preclinical results on the 24 and 25 March, 2011,
respectively, at the Joint Conference - Nutrition, Physical
Activity and Metabolism / Cardiovascular Disease Epidemiology and
Prevention 2011 Scientific Sessions of the American Heart
Association held in Atlanta, GA, USA.
Neptune and Acasti will present clinical results on the superior
absorption of Neptune Krill Oil (NKO®) as compared to competitive
products. Acasti will present efficacy and safety data on its lead
product CaPre™ in a rodent model of the Cardiometabolic
Syndrome.
These upcoming presentations are part of the companies'
continuous effort to raise awareness of both products in the
healthcare community overall for Neptune and especially amongst
cardiologists for Acasti. Neptune will present clinical data
demonstrating higher absorption of EPA and DHA in plasma with NKO®
as compared to other omega-3 and krill oil analogues in the
nutraceutical market. Neptune will also present the advantageous
increase of the Omega-3 Index with a very low 0.5g daily dose of
NKO® compared to all other products tested. On the other hand,
Acasti will present recent results confirming the dual lipid and
glucose management properties of Acasti's prescription drug
candidate, CaPre™. Emphasis will be given to important competitive
preclinical safety results which clearly demonstrate that CaPre™ is
a safe and well-tolerated product, and it is not plagued with
safety issues that have been attributed to other HDL elevating
agents.
"Neptune and Acasti continue to demonstrate the superiority of
their products in the management of risk factors for
Cardiometabolic Syndrome," said the presenting author Dr. Farhad
Amiri, Director, Preclinical Studies, Acasti. "Besides their
significant efficacy, the products' advantageous safety profile
confer to CaPre™ and NKO® the potential of offering a more complete
long-term management and protection against the continuing battle
with dyslipidemia in Cardiometabolic Syndrome," he added.
"The superiority of NKO® on omega-3 pharmacokinetics and the
omega-3 index, a recognized marker for cardiovascular risk,
reinforces the previously proven cardiovascular benefits of Neptune
phospholipids which are important for both Neptune and Acasti,"
said Dr. Wael Massrieh, Vice President, Scientific Affairs of
Neptune. "Furthermore, the observed lack of reflux adds to the
advantages of NKO® over competition reinforcing its priority status
as the prime choice of industry leaders," he added.
"At this stage of our development, we are certainly encouraged
by the comprehensive therapeutic effects and safety profile
exhibited by CaPre™," said Dr. Pierre Lemieux, COO of Acasti. "In
this important AHA session about prevention and nutrition, we will
raise awareness on the low daily recommended dose of CaPre™ which
will substantially help increase compliance and avoid side effects,
contrary to established prescriptions and nutraceutical omega-3s,"
he added.
About Neptune Technologies & Bioressources
Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing consumer
health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health
benefits and to obtain regulatory approval for label health claims.
Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals.
Neptune's products are marketed and distributed in over 20
countries worldwide. Neptune is the mother company of Acasti and
NeuroBioPharm.
About Acasti Pharma Inc.
Acasti Pharma is developing a product portfolio of proprietary
novel long-chain omega-3 phospholipids. Phospholipids are the
major component of cell membranes and are essential for all vital
cell processes. They are one of the principal constituents of High
Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by potent antioxidants. Acasti Pharma is focusing initially on
treatments for chronic cardiovascular conditions within the
over-the-counter, medical food and prescription drug markets.
About Neurobiopharm Inc.
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational partners.
"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release."
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking statements"
within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and Canadian securities laws. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the
actual results of the Company to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are
urged to consider statements labeled with the terms "believes,"
"belief," "expects," "intends," "anticipates," "will," or
"plans" to be uncertain and forward-looking. The forward-looking
statements contained herein are also subject generally to other
risks and uncertainties that are described from time to time in the
Company's reports filed with the Securities and Exchange Commission
and the Canadian securities commissions.
CONTACT: Neptune Contact:
Neptune Technologies & Bioressources Inc.
Andre Godin, V.P. Administration and Finance
+1 450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
CEOcast Contact:
Dan Schustack
+1 212.732.4300
dschustack@ceocast.com
www.ceocast.com
Acasti Contact
Acasti Pharma Inc.
Tina Sampalis, President
+1 450.686.4555
t.sampalis@acastipharma.com
www.acastipharma.com
Howard Group Contact:
Bob Beaty
+1 888.221.0915
bob@howardgroupinc.com
www.howardgroupinc.com
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Sep 2024 to Oct 2024
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Oct 2023 to Oct 2024